ResMed (RMD) Stock Overview
Develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for RMD from our risk checks.
RMD Community Fair Values
Create NarrativeSee what 117 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ResMed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$209.64 |
| 52 Week High | US$293.81 |
| 52 Week Low | US$198.64 |
| Beta | 0.84 |
| 1 Month Change | -6.80% |
| 3 Month Change | -21.50% |
| 1 Year Change | -14.33% |
| 3 Year Change | -10.22% |
| 5 Year Change | 9.01% |
| Change since IPO | 31,102.23% |
Recent News & Updates
Recent updates
New Narrative • May 01
GLP 1 Therapies And Margin Pressures Will Challenge Long Term Earnings Sustainability
Catalysts About ResMed ResMed develops and sells sleep and respiratory care devices, masks and cloud-connected software that support treatment in the home. What are the underlying business or industry changes driving this perspective?
Narrative Update • May 01
RMD: Distribution Expansion And Execution Discipline Will Drive Future Upside
ResMed's updated analyst price target has slipped by about $8 to reflect slightly more cautious assumptions on revenue growth, profit margins, discount rate and future P/E, with several firms trimming targets even as others maintain a constructive view. Analyst Commentary Recent Street research on ResMed has tilted more cautious on valuation, even as one major firm has initiated with a bullish stance.
New Narrative • Apr 27
ResMed (RMD): The Sleep Titan Defies the Weight-Loss Disruptor
ResMed Inc. (RMD) , the global vanguard of cloud-connected sleep and respiratory care, enters the final week of April 2026 in a state of defiant operational strength.Narrative Update • Apr 12
RMD: Distribution Expansion And Margin Strength Will Support Future Upside
ResMed's analyst price target has been nudged lower by about $0.33 as analysts balance a slightly higher discount rate with firmer revenue growth, profit margin assumptions, and modest target increases from several firms alongside a more recent $5 trim from Citi. Analyst Commentary Recent Street research around ResMed reflects a mix of optimism on the company’s execution and growth profile, alongside a more cautious stance on valuation and near term expectations.Narrative Update • Mar 29
RMD: Higher Earnings Visibility And Margins Will Support Future Upside
Analysts have lifted the consolidated ResMed price target by $15, reflecting updated views on its long term growth, margin profile and P/E assumptions in light of recent research from Citi, RBC Capital, Stifel, KeyBanc and Baird. Analyst Commentary Recent Street research points to a cluster of higher price targets for ResMed, with different teams revisiting their assumptions around growth durability, margin structure and the P/E multiple they are willing to apply.Seeking Alpha • Mar 16
ResMed: Waiting For The Next Catalyst, Initiating With Hold Rating
Summary I initiate coverage of ResMed with a Hold rating, citing dominant OSA positioning but near-term competitive headwinds. RMD’s recurring revenue model leverages device sales, consumables, and SaaS, with growth driven by rising diagnosis and treatment rates. Market concerns over GLP-1s and Apnimed’s AD109 may pressure RMD until AD109’s likely 2026–2027 launch clarifies competitive impact. RMD trades at 22x forward P/E versus a 30x historical average, implying 30% upside if valuation normalizes and sales growth persists. Read the full article on Seeking AlphaNarrative Update • Mar 14
RMD: AI Sleep Personalization And New Distribution Hub Will Support Upside
ResMed's analyst price target has edged lower by about $1 to $296.87, as analysts fine tune their models around slightly different fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, while keeping an overall constructive stance. This stance is reflected in a series of recent target increases across the Street.Narrative Update • Feb 28
RMD: AI Sleep Therapy Personalization Will Support Long Term Upside
ResMed's analyst price target has moved higher by several dollars to reflect a modest adjustment to discount rate assumptions, while multiple firms have raised their targets by $3 to $15. Analysts point to supportive fundamentals for the updated view.Narrative Update • Feb 14
RMD: AI Sleep Therapy Personalization And Buyback Will Support Long Term Upside
Our updated ResMed narrative reflects a modest lift in the implied analyst price target to about $297.47, with analysts pointing to slightly higher assumed revenue growth, a small improvement in profit margins, and a marginally lower future P/E multiple as key drivers of the change. Analyst Commentary Recent Street research shows a cluster of upward price target revisions for ResMed, with several firms lifting their targets by between $3 and $15.Narrative Update • Jan 31
RMD: AI Therapy Personalization Will Support Sustained Long Term Upside Potential
Narrative Update on ResMed Analysts have lifted their price targets on ResMed, supporting a modest fair value adjustment to about $296.40 as they factor in updated expectations for growth, profitability, and a slightly lower future P/E assumption. Analyst Commentary Recent Street research on ResMed points to a cluster of price target increases, with several bullish analysts nudging their targets higher by incremental amounts.Narrative Update • Oct 21
Analyst Commentary Highlights Margin Optimism as ResMed Faces Market Headwinds and Patent Challenge
Analysts have raised their price target for ResMed to $295 from $292, citing improved profit margin expectations and better anticipated gross margin expansion. This comes despite concerns over slower market growth dynamics.Analysis Article • Sep 06
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Jul 29
Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Key Insights ResMed's estimated fair value is US$302 based on 2 Stage Free Cash Flow to Equity Current share price of...Analysis Article • Jun 23
Shareholders Would Enjoy A Repeat Of ResMed's (NYSE:RMD) Recent Growth In Returns
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Jun 11
Do ResMed's (NYSE:RMD) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • May 30
There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price
ResMed Inc.'s ( NYSE:RMD ) price-to-earnings (or "P/E") ratio of 27.4x might make it look like a strong sell right now...Analysis Article • May 18
ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Apr 24
ResMed: Cornering The Market In Sleep Solutions
Summary ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, enhancing its product portfolio, customer experience, and expanding into new markets, justifying its premium share price. Concerns about GLP-1 drugs reducing ResMed's market are countered by data suggesting increased overall health engagement, boosting interest in sleep health solutions. ResMed's consistent innovation and market leadership make it a highly attractive investment, despite its shares already trading at a substantial premium. Read the full article on Seeking AlphaSeeking Alpha • Feb 10
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
Summary ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished. Despite an 8.3% stock dip post-earnings, ResMed remains undervalued, trading below its 5-year average P/E ratio, with strong growth prospects supported by innovation and macro trends. Read the full article on Seeking AlphaSeeking Alpha • Feb 01
ResMed: Snoozers Can Be Winners
Summary I believe ResMed is currently overvalued relative to its intrinsic value, making it a good time for investors to take some profits. RMD’s growth has been driven by COVID-19, Philips' product recall, and acquisitions, with a projected growth rate of 9% per year until FY2030. The company's competitive position is strong, with a high ROIC and increasing operating margins, particularly in the SaaS division. Despite the potential impact of GLP-1 drugs, RMD’s demand remains robust, and the company is well-managed with market-leading products. Read the full article on Seeking AlphaSeeking Alpha • Jan 24
ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)
Summary ResMed's share price has outperformed the S&P 500 by ~35% since my October 2023 Buy rating. The stock’s outperformance has been driven by a combination of earnings growth and multiple expansion. Operating conditions for ResMed remain positive, but taking a longer-term perspective, investors should be mindful of downside risks related to GLP-1 drugs and the eventual return of Respironics. ResMed’s valuation now looks slightly stretched, however a supportive near-term outlook is sufficient to justify a Hold rating. Read the full article on Seeking AlphaSeeking Alpha • Nov 25
ResMed: Solid Execution, Pricey Valuation
Summary ResMed Inc., a leader in sleep apnea and respiratory care, posted strong 1Q2025 results late in October. The stock is also up nearly 45% year to date and the analyst community has become quite mixed on the stock's prospects, mainly due to valuation. Is there more upside to this rally in 2024 or is some profit taking overdue? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaShareholder Returns
| RMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.1% | -1.5% | 3.2% |
| 1Y | -14.3% | -19.8% | 31.0% |
Return vs Industry: RMD exceeded the US Medical Equipment industry which returned -19.8% over the past year.
Return vs Market: RMD underperformed the US Market which returned 31% over the past year.
Price Volatility
| RMD volatility | |
|---|---|
| RMD Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RMD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 10,600 | Mick Farrell | www.resmed.com |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution.
ResMed Inc. Fundamentals Summary
| RMD fundamental statistics | |
|---|---|
| Market cap | US$30.15b |
| Earnings (TTM) | US$1.52b |
| Revenue (TTM) | US$5.54b |
20.0x
P/E Ratio5.5x
P/S RatioIs RMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMD income statement (TTM) | |
|---|---|
| Revenue | US$5.54b |
| Cost of Revenue | US$2.09b |
| Gross Profit | US$3.44b |
| Other Expenses | US$1.92b |
| Earnings | US$1.52b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.48 |
| Gross Margin | 62.18% |
| Net Profit Margin | 27.44% |
| Debt/Equity Ratio | 10.2% |
How did RMD perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield22%
Payout RatioDoes RMD pay a reliable dividends?
See RMD dividend history and benchmarks| ResMed dividend dates | |
|---|---|
| Ex Dividend Date | May 14 2026 |
| Dividend Pay Date | Jun 18 2026 |
| Days until Ex dividend | 6 days |
| Days until Dividend pay date | 41 days |
Does RMD pay a reliable dividends?
See RMD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/06 11:09 |
| End of Day Share Price | 2026/05/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ResMed Inc. is covered by 46 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Michael Polark | Baird |
| Matthew Taylor | Barclays |